- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02103101
Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events (Pgp NACO)
Vitamin K antagonists were hampered by several disadvantages, such as the need for frequent monitoring. In this context, new oral anticoagulants (NOACs) have been developed and are now available on the market. These NOACs, like all anticoagulant drugs, continue to be associated with an increased risk of bleeding. In addition, the lack of antidote and the absence of valid data regarding biological monitoring can pose problems in case of overdose or when emergency surgery is required. Studies investigating the pharmacokinetic properties of rivaroxaban and dabigatran, two NOACs now approved for the market, have shown high variability between individuals, with coefficients of variation of up to 60% for some pharmacokinetic parameters in patients treated after orthopaedic surgery. The relation between plasma concentrations of NOAC and bleeding risk has been clearly established in clinical trials.
Dabigtran, rivaroxaban and apixaban are known substrates of P-glycoprotein (Pgp). Pgp activity can be affected by pharmacological inducing or inhibiting agents. This can lead to a significant change in the pharmacokinetics of NOACs, with a decrease or increase (respectively) in the level of intestinal absorption, leading to respectively reduced or increased plasma concentrations of the drug. Furthermore, there exist genetic mutations of Pgp, presenting in particular a lower level of activity than the non-mutated protein. We hypothesized that the polymorphisms (mutations) of the ABCB1 gene that codes for Pgp could influence plasma concentrations of dabigatran, rivaroxaban and apixaban, and consequently, impact on the concentration of NOACs and as a corollary, on the bleeding and thromboembolic risk of patients treated with these molecules.
The main objective of this study is to study the relation between polymorphisms of the ABCB1 gene that codes for Pgp and plasma concentrations of NOACs in patients treated for a hemorrhagic or thromboembolic complication occurring under NOAC therapy.
Secondary objectives are to evaluate the distribution of ABCB1 polymorphisms among the various hemorrhagic risk factors, and to compare the frequency of the polymorphism in patients from the study population vs the general population.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Besancon, France, 25000
- CHU Besançon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged >18 and <80 years of age
- Patients admitted to the University Hospital of Besancon for a serious adverse event (major bleeding complication or thrombo-embolic event) occurring under treatment with any one of the three commercially available new oral anticoagulant agents (rivaroxaban, apixaban or dabigatran).
- Patients must have social security coverage.
- Patients must provide written informed consent.
Exclusion Criteria:
- Hemorrhagic complication from causes not related to drug therapy
- Hemorrhagic complication occurring in patients not treated with oral anticoagulants at the time of the event
- Thrombo-embolic complication occurring in patients not treated with oral anticoagulants at the time of the event
- Legal incapacity, patients under judicial protection
- Patients with no social security coverage
- Patients unlikely to be compliant or anticipated by the investigator to be non-compliant with the study requirements
- Patients in a wash-out period further to participation in a previous clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Study cohort
Measurement of Plasma Concentrations of NOACs Identification of ABCB1 polymorphisms coding for P-gp All patients aged over 18 and less than 80 years admitted for a serious adverse event (bleeding or thrombo-embolic complication) while under treatment with any of the following oral anticoagulant agents: dabigatran, rivaroxaban or apixaban. Blood samples will be drawn to measure plasma concentrations of the oral anticoagulant agent at the time of the adverse event, and presence of polymorphisms of ABCB1 will be investigated. |
Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS).
Blood samples will be taken in an EDTA tube and rapidly centrifugated.
Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of plasma concentrations of new oral anticoagulant agents
Time Frame: 0 days (at inclusion)
|
Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS).
Blood samples will be taken in an EDTA tube and rapidly centrifugated.
Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
|
0 days (at inclusion)
|
Identification of polymorphisms of the gene ABCB1 coding for P-gp
Time Frame: 0 days (at inclusion)
|
To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
|
0 days (at inclusion)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nicolas F Meneveau, MD, PhD, Centre Hospitalier Universitaire de Besancon
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pgp NOAC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemorrhage
-
Region StockholmRecruitingRetinal Hemorrhage, Bilateral | Retinal Hemorrhage, Left Eye | Retinal Hemorrhage, Right EyeSweden
-
Al Hadi HospitalCompletedDiabetic Vitreous HemorrhageKuwait
-
Massachusetts Eye and Ear InfirmaryCompletedPost-operative HemorrhageUnited States
-
Panhandle Eye Group, LLPRecruitingDiabetic Vitreous HemorrhageMexico
-
Weill Medical College of Cornell UniversityThe Edward Grayson Fund for Retinal ResearchUnknownSubretinal Hemorrhage and Exudative MaculopathyUnited States
-
Tel-Aviv Sourasky Medical CenterIsrael Defense ForcesRecruiting
-
Ain Shams Maternity HospitalUnknownPost Operative HemorrhageEgypt
-
Asan Medical CenterUnknownPost Vitrectomy State | Recurrent Diabetic Vitreous HemorrhageKorea, Republic of
-
University of PisaCompletedPost Operative HemorrhageItaly
-
Cairo UniversityCompletedPost Operative HemorrhageEgypt
Clinical Trials on Measurement of Plasma Concentrations of NOACs
-
Rennes University HospitalRecruitingBlood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, TucatinibFrance
-
General Hospital Sveti DuhCompleted
-
Changi General HospitalRecruitingObstructive Sleep Apnea | Pheochromocytoma | Catecholamine; SecretionSingapore
-
Assistance Publique - Hôpitaux de ParisUnknownCovid-19 | Critical Illness | SARS-CoV Infection | HemodynamicsFrance
-
University Hospital for Infectious Diseases, CroatiaCroatian Science FoundationRecruitingSepsis | Immune Response | Steatosis of LiverCroatia
-
Hospital AvicenneRoche Diagnostics; ProBayes; Biorance Laboratoires RéunisCompletedBiological Markers | Inappropriate PrescribingFrance
-
Radboud University Medical CenterCompletedParoxysmal Nocturnal Hemoglobinuria | Eculizumab | PK-PDNetherlands
-
University Hospital, Clermont-FerrandUnither PharmaceuticalsCompleted
-
Liverpool John Moores UniversityCompleted
-
Virginia Commonwealth UniversityDaxor CorporationWithdrawn